Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...

An announcement from Perspective Therapeutics ( ($CATX) ) is now available. On December 1, 2025, Perspective Therapeutics updated its corporate ...

Emerging Growth Conference 88 December 11, 2025 9:05 AM ESTCompany ParticipantsJean-Marie Clouet - Vice President ...

IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).

Akeso, Inc. (9926.HK) (Akeso or the Company) announced the presentation of a Phase II clinical study that included a ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

In recent days, Rocket Companies participated in high-profile presentations at both the Stephens Annual Investment Conference and Deutsche Bank's Financial Services IRO Summit, highlighting its ...

Q3 2026 Earnings Call Transcript November 25, 2025 Petco Health and Wellness Company, Inc. beats earnings expectations.

Presentation included previously disclosed primary results from the pivotal ARES Phase 3 single-arm trial evaluating MaaT013 (Xervyteg) in treating refractory severe acute Graft-versus-Host Disease ...

The Prada Group announced Tuesday that it has officially purchased Milan fashion rival Versace in a 1.25 billion euro (nearly ...

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 million (14% growth midpoint); AOI expected at $41 million to $44 million (19% ...